WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data

NCT ID: NCT03210285

Last Updated: 2018-07-23

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 70 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-07-31
• Study Completion Date: 2018-07-01

Brief Summary

Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults. The aim is to gain insight into the complete genome of the NF2 associated VS compared to sporadic VS (control group). These data are to be correlated with the clinic, ie the auditory function (audiogram, acoustically evoked potentials) and the clinical picture as well as the tumor growth rate and general data such as sex, age, side, etc.

Detailed Description

Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults. The aim is to gain insight into the complete genome of the NF2 associated VS compared to sporadic VS (control group). These data are to be correlated with the clinic, ie the auditory function (audiogram, acoustically evoked potentials) and the clinical picture as well as the tumor growth rate and general data such as sex, age, side, etc.

The analysis of genetic changes should provide a better insight into the oncogenesis of these tumors. The distinct genetic characteristics between NF2-associated and sporadic VS suggest a different oncogenesis of these tumors.

The correlation of the genetic characteristics with the partly very different clinical appearance and a very different dynamics of the disease, in particular the tumor volume in the course, identifies the underlying modifiers of the disease course.

Based on these genetic modifiers, patients can be stratified and individual clinical therapy decisions can be made.

By demonstrating these genetic profiles in the peripheral blood, prospective conclusions can be drawn about expected disease progression before intervention as well as for therapy monitoring

Conditions

Neurofibromatosis Type 2; Vestibular Schwannoma; Acoustic Neuroma

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: OTHER

Study Groups

NF2-associated VS

Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue

Whole exome sequencing

Intervention Type: DIAGNOSTIC_TEST

Whole exome sequencing

Sporadic VS

Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue

Whole exome sequencing

Intervention Type: DIAGNOSTIC_TEST

Whole exome sequencing

Interventions

Whole exome sequencing

Whole exome sequencing

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Study population: Operated NF2-associated VS
• Control group: Operated sporadic VS
• Consent to participation in the study by the patient / legal guardian in prospective inclusion or consent to the use of stored specimens in retrospective inclusion
• Age: 0 -99 years

Exclusion Criteria

• Lack of informed consent
• Patient's request (withdrawal of the consent statement for the evaluation of the data and further storage of the blood / tissue samples)

• Minimum Eligible Age: 1 Day
• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Center for Tumor Diseases, Heidelberg

OTHER

Sponsor Role: collaborator

University Hospital Tuebingen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Martin Schuhmann, Prof. Dr.

Role: STUDY_DIRECTOR

University Hospital Tübingen

Locations

University Department of Neurosurgery Tübingen

Tübingen, , Germany

Countries

Germany

Other Identifiers

NF2Tue

Identifier Type: -

Identifier Source: org_study_id